INS and cystic neoplasm: If surgical removal of cystic tumours is indicated, the risk of perioperative complications, mortality and impairment of quality of life, the substitution of pancreatic enzymes and any insulin medication after pancreatic resection must be weighed against the risk of malignant degeneration that is already present or occurs during the course of the procedure.